Skip to content

Knowledge builds confidence.

Confidence empowers decisions.

Make It Make Sense (MIMS) is here to help you understand clinical trials and explore your options so you can have more informed conversations and make decisions that are right for you.

Understand

Understand

Clear, easy-to-understand information about HER2-positive early breast cancer.

Explore

Explore

Learn about clinical trials and how research is advancing treatment options.

Ask

Ask

Get questions to help you start conversations with your healthcare team.

Empower

Empower

Feel confident making informed decisions about your care and your future.

This Months Focus

This Month’s Focus

What Is HER2-Positive Early Breast Cancer?

Every person’s diagnosis is unique, and understanding your specific subtype can help inform conversations about treatment options, including clinical trials.

HER2-positive breast cancer is a type of breast cancer in which cancer cells produce higher-than-normal amounts of the HER2 protein. While HER2-positive cancers tend to grow and spread faster than other subtypes, advances in targeted therapies have improved outcomes for many patients.

Treatment options may include:

Surgery | Chemotherapy (when appropriate) | HER2-targeted therapies | Radiation therapy | Ongoing follow-up care

Why Are Clinical Trials Important?

Clinical trials help researchers discover new ways to:

Improve treatment effectiveness
Reduce side effects
Personalize care
Improve quality of life
Advance future standards of care

Clinical trials are an important option for many people and may be available at different stages of breast cancer.

our-promise

Our Promise

MIMS is designed to provide clear, unbiased educational information about clinical trials so you can have informed conversations with your healthcare team.

“Participation in a clinical trial is always your choice.”

BC-303 (EmpowHER-303) Study

Trial Evaluating Zanidatamab in Metastatic HER2-Positive Breast Cancer (NCT06435429)
 
Designed to evaluate investigational treatment approaches for individuals with HER2-positive breast cancer.
 
Metastatic means breast cancer has spread to another part of the body.
 
Learn More » myher2trial.com

BC-208 (EmpowHER-208) Study

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (EmpowHER 208) (NCT07102381)
 
Exploring additional treatment strategies that may improve outcomes for eligible patients diagnosed with HER2-positive early breast cancer. 
 
Neoadjuvant means treatment given before surgery.
 

Talk with your healthcare team to see if a clinical trial may be right for you.

More About Clinical Trials →

Explore Trusted Resources

Start here to learn more about HER2-positive early breast cancer and clinical trial options.

Learn About HER2-Positive Early Breast Cancer

Learn About HER2-Positive Early Breast Cancer

Understand your diagnosis, treatment options, and what to expect.

Explore Clinical Trial Opportunities

Explore Clinical Trial Opportunities

Learn how clinical trials work and how they may help you or others.

Find Questions to Ask Your Doctor

Find Questions to Ask Your Doctor

Helpful questions to guide your next conversation.

Learn About Clinical Trial Participation

Learn About Clinical Trial Participation

Understand the process, your rights, and what to expect.

Sponsored by

JAZZ_BIG-8c2ac29f

Tigerlily Foundation thanks Jazz Pharmaceuticals for their support of the Make It Make Sense (MIMS) initiative. Their partnership helps expand patient education and clinical trial awareness so more women can access the information they need to make empowered decisions.